fbpx

SOT THERAPY

Supportive Oligonucleotide Technique (SOT) for Lyme Disease, Infections, & Cancer

Supportive Oligonucleotide Therapy (SOT)- A One-Stop Gene Therapy

Dr. Sponaugle is happy to inform you that we now offer Supportive Oligonucleotide Therapy (SOT) as one of our many treatment modalities for viral infections, Lyme Disease, and various coinfections.

What is SOT Therapy?

Supportive Oligonucleotide Therapy (SOT) is a process that enables the RGCC lab to identify the specific gene sequences of different targets such as cancer, Lyme, and various viruses and design a specific oligonucleotide therapy.

SOT therapy is a groundbreaking treatment for chronic infections, including the bacteria causing Lyme disease and associated co-infections. Due to the complexity of how these infections can hide from the human immune system, essentially a chronic persisting disease, SOT is a way of educating our cells to be more efficient at finding them.

This modality is especially important for patients with viral etiologies, especially those in the Herpes/Epstein Barr family, as they all cause cancer, tend to infect the brain, and suppress natural killer cell production, making it more difficult to kill other viruses and bacteria like Lyme, Bartonella, etc.

At Sponaugle Wellness, we have seen fantastic progress with their use in our patients to address viral and bacterial infections, particularly Epstein-Barr virus, herpes hsv1/hsv2, tickborne infections, HPV, and other infections.

How Does SOT Therapy Work?

At the Sponaugle Wellness Institute in Oldsmar, Florida, patients schedule a single-day trip to the clinic for a blood draw to generate a blood sample to be sent to the RGCC lab in Greece. Prior to arrival, patients are instructed to avoid treatments such as antibiotics, ozone, and infusions that lower the levels of infection in the body.

The patient's blood is sent to RGCC, and they identify the appropriate gene that needs to be silenced. Once they detect the potential genes for targeting, they validate these targets in silica and in vitro. The validation of the target ensures the highest specificity and does not interfere with any other marks.'

After confirmation of infection is established, the patient’s blood is drawn to obtain circulating Lyme bacteria or viruses. RGCC lab identifies the main genetic sequence of the target replication genes for the organism, then creates a complementary oligonucleotide (short nucleic acid) sequence to block replication. It takes about four weeks to develop a SOT.

Once the different target genes have been validated, the most appropriate is selected, and the laboratory creates an oligonucleotide complementary to the mRNA for a specific region of this gene. This, in turn, creates anti-sense therapy.

These molecules are delivered to our clinic, where the then patient receives the one-dose IV treatment. Once the patient is administered the SOT molecules, they work 24 hours a day, seven days a week, for up to six months, inhibiting the appropriate gene.

When completed, the RGCC ships the SOT back to the clinic, where it is then infused intravenously and administered to the patient for about an hour. Intravenous antihistamines and low-dose steroids are given immediately before SOT administration to lessen the already rare chance of an allergic reaction and tighten the vein walls to minimize the leaking of SOT.

What is the Mechanism of Action for SOT Therapy?

SOT creates a shutoff “key” fitting a “lock” portion of a pathogen that prevents the bacteria/virus from making essential proteins and shutting off bacterial/viral replication.

The “lock” is a specific section of DNA that normally controls an important function of the pathogen.

The “key” binds to the “lock” and blocks the cell's function and replication – thereby killing the cancer cell or pathogen and preventing its replication.

Unable to replicate, the bacteria/virus cannot cause disease but instead begin a self-destruction process called apoptosis.  This treatment works 24/7 in the body for three–six months and can be used while continuing other treatment modalities. You can even continue natural medication therapies without interaction.

If a patient has multiple active infections, multiple SOT treatments will be needed for each infection.

Through the replication of genes and then the creation of an antisense copy, the abnormal genes are silenced.  In the laboratory, 500 million-1 billion copies of the unique SOT molecule are formulated.

Sot therapy for lyme disease
SOT Therapy Mechanism of Action for Lyme Disease

What is the goal of SOT Therapy?

SOT Therapy aims to inhibit the expression of proteins essential for cell metabolism and/or survival targeted viruses and bacterial infections. The SOT is uniquely tailored to each patient's needs. It is a small oligonucleotide complementary to a specific sequence of individual genes related to anti-apoptotic signals inside cancer cells or genes essential for microorganisms and viruses' survival or metabolism. Apoptosis is another word for programmed cell death. In other words, the SOT molecule has a potent ability to block specific mRNA with a very high specificity rate. Therefore, the expression of the desired gene is inhibited.

What is the Mechanism of Action for SOT Therapy?

SOT creates a shutoff “key” fitting a “lock” portion of a pathogen that prevents the bacteria/virus from making essential proteins and shutting off bacterial/viral replication.

The “lock” is a specific section of DNA that normally controls an important function of the cancer cell or pathogen.

The “key” binds to the “lock” and blocks the cell's function and replication – thereby killing the cancer cell or pathogen and preventing its replication.

Unable to replicate, the bacteria/virus cannot cause disease but instead begin a self-destruction process called apoptosis.  This treatment works 24/7 in the body for three–six months and can be used while continuing other treatment modalities. You can even continue natural medication therapies without interaction.

If a patient has multiple active infections, multiple SOT treatments will be needed for each infection.

Through the replication of genes and then the creation of an antisense copy, the abnormal genes are silenced.  In the laboratory, 500 million-1 billion copies of the unique SOT molecule are formulated.

SOT and Antisense Oligonucleotides

SOT therapy utilizes molecular building blocks (mRNA) found naturally in the patient’s body. Nucleotides are the molecules that form the structure of DNA and RNA.

Nucleotides are the molecules that form the backbone of our DNA.  Oligo means “few” or “small.”  Oligonucleotides are short single-strand DNA molecules.  The creation of a specific oligonucleotide intended to bind to its counterpart in the body is called an “antisense” oligonucleotide.  Antisense implies the mirror image or the “lock and key” analogy.

SOT therapy creates an oligonucleotide that is complementary to a specific sequence for each gene. It is designed to bind to this gene’s counterpart (mirror image) in the body, thus blocking its function. It blocks a specific target at a very high rate – stopping the expression and transcription of a specific gene. SOT terminates gene replication sequences, thus eradicating pathogens or cancerous cells from the body and preventing future lifecycles of these cells.

The SOT is a small oligonucleotide that is complementary to a specific sequence of each gene which is related to the most active target options inside the cancer cell, viruses, or Lyme bacteria (e.g., acylguanidines, RNA, non-nucleoside transcriptase, etc.).  This is based on each individual and the most active target for that individual.

The SOT life span is increased by a proprietary technology that makes this molecule unrecognizable by the enzymes that normally break down oligonucleotides and, at the same time, helps the SOT keep the same solubility feature membrane penetration and other complementary hallmarks as the normal oligonucleotides.

Hence, the SOT has a potent ability to block a specific target and, at a very high rate, the expression and transcription of a gene that encodes a protein with one of the target options used. Since the molecule is not degraded, the complementary mRNA releases the SOT to move to the next target with the same sequence. Hence, one molecule of SOT can potentially block many other relative marks in a very specific way. Therefore, death can be re-engaged in cancer cells, viruses, and Lyme bacteria.

Finally, since it is complementary to one of the target options inside cancer cells, viruses, and Lyme bacteria, it is highly specific to these only. It will only work for the patient that it was made for.  The SOT rarely causes adverse reactions since it is highly compatible with the organism.

Available Viral  SOTs

  • HHV1/HSV1 — (Human Simplex Virus-Oral-Facial)
  • HHV2/HSV2 — (Human Simplex Virus-Genital)
  • HHV6 (A & B) — (Human Herpes Virus 6)
  • CMV — (Cytomegalovirus)
  • Coxsackie (Type A & B)
  • VZV — Varicella-zoster (shingles)
  • EBV — (Epstein Barr)
  • HPV (16/18) — Human papillomavirus
  • HPV (6/11) — Human papillomavirus
  • HBV — (hepatitis B)
  • HCV — (hepatitis C)
  • HIV — (human immunodeficiency virus)-AIDS
  • HTLV1— (human T-cell lymphotropic virus)

Available Lyme/coinfection SOTs

Borrelia Species

  • afzelii
  • bavariensis
  • bissettii
  • burgdorferi
  • californiensis
  • finlandensis
  • garinii
  • genomospecies
  • hermsii
  • kurtenbachii
  • lusitaniae
  • mayonii
  • miyamotoi
  • recurrentis
  • sinica
  • turcica
  • turicatae
  • valaisiana
  • Candidatus Borrelia tachyglossi

Bartonella Species

  • bacilliformis,
  • elizabethae
  • henselae,
  • quintana,
  • vinsonii

Babesia Species

  • Babesia bigemina
  • Babesia bovis
  • Babesia divergens
  • Babesia duncani
  • Babesia microti

Other tick-borne bacterial diseases

  • Anaplasma phacocytophilum
  • Rickettsia rickettsia
  • Ehrlichia chaffeensis

SOT for Lyme Disease & Tickborne Coinfections

SOT treatment consists of tiny oligonucleotides that “match” the precise sequence of particular genes of the Lyme bacterium species, co-infection bacteria, or virus we attempt to eradicate.

SOT therapy is always on the lookout for the Lyme species or virus to target. Lyme bacteria and viruses send out signals to multiply themselves regularly. Because the SOT molecules block that communication and force the bacterium or virus cells to self-destruct, the Lyme bacteria or virus we’re treating dies. It operates 24 hours a day, seven days a week, and does not lose effectiveness over (up to) six months. As a result, we can “switch off” the Lyme illness, Lyme co-infections, and viral replication cycle.

SOT is now available for many viral infections, including Epstein-Barr, CMV, herpes, HHV-6, HIV, hepatitis, HPV, and others, as well as for Lyme, Ehrlichia, Babesia, and Bartonella.  Once administered, the SOT works by inhibiting gene replication to these infections.

In addition, the immune function of each patient needs to be optimized after evaluation.  This therapy is utilized in conjunction with autologous cancer vaccines, dendritic cell vaccines, and checkpoint inhibitors.  Low-dose personalized chemotherapy and natural substances are also utilized for cancer.  If you suffer from chronic infections, we can help you with SOT.  Immune function optimization before receiving SOT is imperative.

 

Sot therapy for lyme disease
SOT Therapy for Lyme Disease

The figure shows an example of a pathogen such as the Lyme bacteria. Inside the cell nucleus (yellow), bacterial DNA is used to transcribe messenger RNA (mRNA). The mRNA is sent out of the nucleus into the main part of the cell, the cytoplasm. There, mRNA joins amino acids into proteins essential for various bacterial activities, including reproduction.

SOT therapy works by creating a short segment of complementary DNA in the lab that binds to the specific mRNA segments and prevents the bacteria from making essential proteins, essentially shutting off bacterial replication. Unable to replicate, the bacteria are unable to cause disease.

SOT therapy is not a drug in the traditional sense. It is not an antibiotic, nor is it gene therapy. It does not change the genetic structure. There is no gene splicing, gene insertion, or manipulation. SOT therapy is a stealth technology with small molecules that can avoid detection and destruction by the immune system or RNA degrading enzymes for months, allowing them to quietly circulate through the body, attaching to their viral or bacterial targets.

What are the side effects of SOT Therapy?

As the SOT is derived from the patient’s blood, the side effects are usually minimal. The main side effects of SOT treatment are detox or “Herx” reactions, such as fatigue, body aches, fever, and headache. Patients who have gone through treatment often say, “your symptoms get worse before they get better.”

The SOT may be repeated up to 3x per year if needed. With each round of SOT, it is recommended to retest for the presence of pathogens. Eventually, the infection may be completely eradicated or remain stable in quiet remission.

Scroll to Top
Skip to content